Oral triple metronomic chemotherapy is effective in second line relapsed refractory HNSCC . Phase 3 RCT Congratulations Vanita Noronha, MBBS MD DM ASCO OncoAlert kothari rushabh #asco23 TMH Medical Oncology Alumni ACTREC-TMC Pramesh CS

Our study covered by ecancer CRSF - Cancer Research and Statistic Foundation Dr (Prof). Vijay Patil 2L triple metronomic chemo has an OS and PFS advantage over systemic therapy for head and neck cancer - ecancer ecancer.org/en/video/11319…

And that's a wrap for #ASCO23! We are thrilled to witness the unwavering commitment of everyone involved in the fight against cancer. Your dedication is truly inspiring. Shout out to influencers on Day 5: Kimmie Ng, MD, MPH, Oncology Brothers, Julie Gralow, Vivek Subbiah, MD, Samer Al Hadidi, MD,MS,FACP,

Pleasant surprise CRSF - Cancer Research and Statistic Foundation Narayana Health

#NewProfilePic

#Metronomic #Chemotherapy performs well in second-line head and neck #Cancer 👉bit.ly/3P7lyLj MDedge Hematology & Oncology Jim Kling #Survival

amazing collective effort from the group.. congratulations 🎊 research which matters and changes practice on the ground.. enough evidence to indicate that OMCT backbone with immunotherapy must be studied in a frontline trial.. The ASCO Post Dr Amol Akhade LARVOL Praveen Kumar Marimuthu Ajoy Oommen John

Phase 3 Study on Triple Metronomic Therapy Now Published in The Cancer Letter - Rushabh Kothari kothari rushabh Ashish Singh oncodaily.com/insight/triple… #Cancer #Oncology #Health #Medicine #OncoDaily CancerWorld